SGMO: Summary for Sangamo BioSciences, Inc. - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Wednesday, February 10, 2010, 5:25am EST - Canadian Markets open in 4 hours and 5 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

Sangamo Biosciences Inc. (SGMO)

On Feb 9: 4.85 USD 0.00 (0.00%)

MORE ON SGMO

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

Sangamo BioSciences, Inc. (NGM:SGMO) Delayed quote data

Last Trade:	4.85 USD
Trade Time:	Feb 9
Change:	0.00 (0.00%)
Prev Close:	4.85
Open:	N/A
Bid:	N/A
Ask:	N/A
1y Target Est:	8.40

Day's Range:	N/A - N/A
52wk Range:	2.68 - 9.39
Volume:	0
Avg Vol (3m):	259,616
Market Cap:	217.80M
P/E (ttm):	N/A
EPS (ttm):	-0.44
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y max

Add SGMO to Portfolio

Download Data

HEADLINES

•	New Star Analyst Rankings for Sangamo BioSciences, Inc.
	StarMine (Thu, Feb 4)

•	Sangamo BioSciences, Inc. Q4 2009 Earnings Call Transcript
	at Seeking Alpha (Wed, Feb 3)

•	SANGAMO BIOSCIENCES INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E
	EDGAR Online (Wed, Feb 3)

•	Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results
	PRNewswire (Wed, Feb 3)

•	Q4 2009 Sangamo BioSciences Earnings Release - After Market Close
	CCBN (Wed, Feb 3)

•	Sangamo BioSciences Announces Presentation at BIO CEO & Investor Conference
	PRNewswire (Mon, Feb 1)

•	Sangamo BioSciences Announces Fourth Quarter and Full Year 2009 Conference Call and Webcast
	PRNewswire (Wed, Jan 27)

•	Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 1 Safety Trial of SB-728-T for HIV/AIDS
	PRNewswire (Tue, Jan 19)

•	Stocks to Watch at BiotechÂs Bellwether Conference
	at Minyanville.com (Mon, Jan 11)

•	Sangamo plans another mid-stage neuropathy trial
	at Reuters (Mon, Jan 11)

More Headlines for SGMO...

ANALYST

EPS Est (next year) (Dec-10) :	-0.37
EPS Est (in 2 years) (Dec-11) :	-0.15
Avg Rec (current)*:	2.4
PEG Ratio:	N/A

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

Sangamo BioSciences, Inc. engages in the research, development, and commercialization of zinc finger DNA-binding proteins (ZFPs) for gene regulation and gene modification in the United States.

Full Company Profile

Add to Portfolio

Email to a Friend

•